All In Biotech

Free tool

FAERS Monitor: Opfolda

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215211 or its brand name (Opfolda, Miglustat). Reports on generic versions are filed under their own applications.

Reports

264

Serious

186

70% of reports

Hospitalization

105

Death reported

30

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pneumonia24
  • seizure24
  • diarrhoea20
  • vomiting15
  • off label use14
  • nausea12
  • pyrexia12
  • asthenia11
  • condition aggravated11
  • fatigue11
  • respiratory failure11
  • weight decreased11
  • dysphagia10
  • dyspnoea10
  • fall10

Reports by year received

View as table
YearReports
20061
20101
20114
20123
20133
20171
201810
201912
202011
202116
202218
202321
202451
202564
202648

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,895 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
seizureSignal2416.611.3337
respiratory failureSignal1112.06.7101
dysphagiaSignal108.44.658
pneumoniaSignal245.94.094
weight decreasedSignal113.11.814
condition aggravatedSignal112.91.612
pyrexiaSignal122.81.612
vomitingSignal152.51.613
diarrhoeaSignal202.51.617
fallSignal102.41.37
astheniaSignal112.31.37
dyspnoea101.40.81
off label use141.30.81
nausea121.20.70
fatigue111.10.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.